Camizestrant Links ESR1 Detection to Breast Cancer Care

The decision turns serial molecular testing into a treatment decision point for a defined group of patients with hormone receptor-positive, HER2-negative disease. Rather than waiting for conventional progression, clinicians can identify an emerging ESR1 mutation in circulating tumor DNA and, when all label criteria are met, replace the aromatase inhibitor with camizestrant while maintaining CDK4/6 inhibition.

This is a narrower indication than simply finding any ESR1 alteration at any point in advanced breast cancer. The timing of detection, current treatment, disease status and testing method all matter. An ESR1 mutation indicates eligibility only within the population and circumstances described by the FDA-approved labeling.

Why an emerging ESR1 mutation matters

ESR1 encodes estrogen receptor alpha, the principal target of endocrine treatment in most hormone receptor-positive breast cancers. Mutations in the ligand-binding domain can allow estrogen-receptor signaling to continue despite estrogen deprivation, creating resistance to aromatase inhibitors.

These mutations are often selected under treatment pressure. A tumor that was ESR1 wild-type at diagnosis can acquire a detectable mutation after exposure to an aromatase inhibitor, particularly in advanced disease. An older tissue specimen may therefore fail to represent the tumor’s current molecular state.

Blood-based circulating tumor DNA testing can detect that evolution during treatment. In this setting, the clinically relevant signal is an ESR1 mutation becoming detectable while the patient is receiving an aromatase inhibitor with a CDK4/6 inhibitor but has not yet developed radiographic progression. The mutation is not merely prognostic information: under the new approval, it can establish eligibility for an endocrine switch.

Camizestrant is an oral selective estrogen-receptor degrader and complete estrogen-receptor antagonist. Its role here is not to replace the entire regimen. The evidence evaluated switching from an aromatase inhibitor to camizestrant while continuing CDK4/6 inhibition.

Evidence behind the treatment switch

The pivotal evidence came from SERENA-6, a randomized, double-blind phase 3 trial in patients with hormone receptor-positive, HER2-negative advanced breast cancer. Participants received first-line aromatase inhibitor and CDK4/6 Inhibitor therapy and underwent serial circulating tumor DNA testing. Those with a newly detected ESR1 mutation and no radiographic disease progression could enter the randomized comparison.

A total of 315 patients were assigned to switch the aromatase inhibitor to camizestrant or to continue the aromatase inhibitor, with the existing CDK4/6 inhibitor maintained in both groups. This design isolated the effect of changing the endocrine component at molecular progression rather than waiting for clinical or imaging-defined progression.

At a median follow-up of approximately 12 months, median progression-free survival was 16.0 months with camizestrant and 9.2 months with continued aromatase-inhibitor therapy. The hazard ratio for disease progression or death was 0.44 (95% CI, 0.31 to 0.60), with a P value below 0.0001.

The result supports a causal treatment effect within the randomized population. It does not establish that every ESR1 mutation requires an immediate switch, nor does it show that the strategy applies to patients outside the trial and label criteria. Overall survival follow-up was not mature enough to determine whether earlier switching prolongs life.

What changes in practice

The approval links treatment eligibility to longitudinal testing rather than a one-time baseline profile. A negative ESR1 result before or early in treatment does not rule out later emergence because resistant clones may become detectable only after months of aromatase-inhibitor exposure.

Implementation therefore requires a planned pathway: determine who meets the disease and treatment criteria for monitoring, obtain testing at clinically appropriate intervals, confirm that the assay and specimen meet labeling requirements, and act on a positive result only after checking that radiographic progression has not already occurred. The FDA maintains a list of cleared or approved companion diagnostic devices, but clinicians should consult the current camizestrant label for the required test and specimen details.

The distinction between molecular and radiographic progression is central. SERENA-6 did not test camizestrant as rescue therapy after overt progression on the same regimen. It tested a preemptive endocrine switch prompted by an emerging resistance mutation while the current combination was still controlling disease on imaging.

The evidence also supports continuing the CDK4/6 inhibitor used before mutation detection, rather than assuming that the entire regimen has failed. That conclusion is specific to the studied strategy. It should not be generalized to other endocrine drugs, other resistance mutations or later treatment lines without supporting evidence.

Important limits and unanswered questions

The randomized design provides strong evidence for improved progression-free survival, but follow-up was relatively short and overall survival remained unresolved. Longer observation is needed to learn whether delaying radiographic progression translates into longer survival or changes the effectiveness of later treatment.

Generalizability is another limitation. Trial participants had a specific breast cancer subtype, were receiving first-line aromatase-inhibitor plus CDK4/6-inhibitor therapy, developed detectable ESR1 mutations and had no radiographic progression. Patients with prior progression, different endocrine backbones, ESR1 mutations found only in archived tissue, or substantial comorbidity may not have been represented adequately.

Serial circulating tumor DNA testing also introduces practical uncertainties. Mutation abundance can be low, assays differ in analytic sensitivity, and some tumors shed little DNA into plasma. A negative blood result does not always establish that an ESR1-mutant clone is absent. Access, coverage, turnaround time and coordination with imaging may determine whether the trial strategy can be reproduced consistently.

Interpret safety in the context of continued combination therapy. Adverse events may arise from camizestrant, the CDK4/6 inhibitor or both. Clinicians should use the FDA label for contraindications, warnings, laboratory monitoring, drug interactions and treatment modifications rather than extrapolating from progression-free survival results.

Questions clinicians ask

Does any positive ESR1 test make a patient eligible?

No. The approval applies to a defined clinical setting involving the appropriate breast cancer subtype, locally advanced or metastatic disease, mutation detection during aromatase-inhibitor plus CDK4/6-inhibitor therapy and the absence of radiographic progression. Check the current FDA label for every eligibility and testing requirement.

Should archived tumor tissue be retested instead of using blood?

Archived tissue may document an existing mutation but can miss resistance that emerged during therapy. SERENA-6 used serial circulating tumor DNA testing to identify newly detectable ESR1 mutations, making a current blood-based result central to the evidence. The approved test and acceptable specimen type remain label-dependent.

Is the CDK4/6 inhibitor stopped when camizestrant begins?

The studied strategy maintained CDK4/6 inhibition and replaced the aromatase inhibitor with camizestrant. The trial therefore supports changing the endocrine component rather than abandoning the entire regimen, but only for patients matching the trial and FDA indication.

Has the strategy been shown to improve overall survival?

Not yet. The randomized trial showed a statistically significant progression-free survival benefit, but follow-up was insufficient to draw a definitive overall survival conclusion. Continued reporting will be important because an early switch could also affect the timing and effectiveness of subsequent treatment.

References

1. Novel Drug Approvals for 2026 — U.S. Food and Drug Administration, 2026 2. A Study of Camizestrant in ER+/HER2- Early Breast Cancer After Detection of an ESR1 Mutation During First-Line Treatment (SERENA-6) — ClinicalTrials.gov, 2025 3. List of Cleared or Approved Companion Diagnostic Devices — U.S. Food and Drug Administration, 2026